Alpha Tau Medical’s (DRTS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2025 earnings at ($0.53) EPS.

Alpha Tau Medical Stock Down 0.8 %

Shares of NASDAQ DRTS opened at $2.60 on Monday. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $4.39. The company has a market cap of $181.80 million, a PE ratio of -6.05 and a beta of 0.87. The business’s 50 day moving average price is $3.23 and its two-hundred day moving average price is $2.79.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). As a group, research analysts anticipate that Alpha Tau Medical will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of large investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. raised its stake in Alpha Tau Medical by 2.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after acquiring an additional 7,189 shares during the period. Northern Trust Corp raised its stake in Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after acquiring an additional 25,770 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after buying an additional 26,800 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.